Type 2 Diabetes and obesity are the key threats to global health, and it is a pandemic. The gut hormones such as GLP-1 and Glucagon, regulate energy homeostasis and metabolism. The analogs having action on both GLP-1 and Glucagon receptors have shown promise for the treatment of T2D and obesity. This presentation will discuss a highly selective Glucagon agonist (ICA 1560349) in combination with Exenatide, a GLP-1 selective agonist demonstrates a significant reduction of body weight and Glucose in rodents, and have the potential for the treatment of obesity and T2DM.